Kebilidi
Kebilidi ingredients
| Active ingredient | Strength |
|---|---|
| Eladocagene Exuparvovec | 560000000000 {GC}/mL |
What Kebilidi is used for
The FDA lists the approved uses on the official label (below). In the EU, eladocagene exuparvovec is approved as Upstaza for:
Upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L amino acid decarboxylase (AADC) deficiency with a severe phenotype (see section 5.1).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Kebilidi
- Generic name
- Eladocagene exuparvovec-tneq
- Made by
- PTC Therapeutics, Inc.
- Forms
- Suspension
- Given
- Intracerebral
- FDA approval
- Biologic licence (BLA) BLA125722
- On the US market since
- 2024
Official information
- Kebilidi prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Eladocagene exuparvovec-tneq)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kebilidi?
Kebilidi (Eladocagene exuparvovec-tneq) is a specialist medicine made by PTC Therapeutics, Inc., approved by the US FDA.
What are the ingredients of Kebilidi?
Kebilidi contains Eladocagene Exuparvovec (560000000000 {GC}/mL).
Is Kebilidi approved in Europe?
The same active substance is approved in the EU as Upstaza.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA